Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World DataGuofeng Chen, George Lau, Lai Wei et al.|PLoS ONE|2016Cited by 44
Increase in Incidence of Hepatocellular Carcinoma in Chronic Hepatitis C Chinese After Sustained Virologic Response with Direct Acting Antiviral Agents as Compared to Pegylated Interferon Plus Ribavirin Therapy: A Prospective Open-Label StudyDong Ji, George Lau, Ping Han et al.|SSRN Electronic Journal|2019Cited by 2
Assessment of significant hepatic damage in young patients with chronic hepatitis B to initiate the antiviral treatment: The APLB scoreYifan Guo, Dong Ji, Xiao-Huan Wu et al.|Antiviral Research|2025Cited by 0